Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclarion Equity Warrant Exp 1st Dec 2026 ACONW

Healthcare Medical Devices
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the... see more

Recent & Breaking News (NDAQ:ACONW)

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

GlobeNewswire 3 days ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Accesswire 9 days ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 10, 2024

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

GlobeNewswire September 27, 2024

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

GlobeNewswire September 12, 2024

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

GlobeNewswire September 10, 2024

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

GlobeNewswire September 5, 2024

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

GlobeNewswire August 29, 2024

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

GlobeNewswire August 21, 2024

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

GlobeNewswire August 15, 2024

Aclarion Announces First Commercial Agreement in Michigan

GlobeNewswire August 14, 2024

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

GlobeNewswire August 13, 2024

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

GlobeNewswire July 9, 2024

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

GlobeNewswire June 26, 2024

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

GlobeNewswire June 25, 2024

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

GlobeNewswire April 25, 2024

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

GlobeNewswire March 4, 2024

Aclarion Announces Closing of $3.0 Million Public Offering

GlobeNewswire February 27, 2024

Aclarion Announces Pricing of $3.0 Million Public Offering

GlobeNewswire February 26, 2024

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

GlobeNewswire February 5, 2024